Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RDHL
RDHL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RDHL News
RedHill Biopharma Enters ADS Purchase Agreement
2d ago
seekingalpha
RedHill Biopharma Completes Private Placement Financing
2d ago
PRnewswire
RedHill Biopharma Receives FDA Rare Pediatric Disease Designation for Opaganib
Jun 09 2026
NASDAQ.COM
FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma Treatment
Jun 09 2026
PRnewswire
FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma
Jun 09 2026
Newsfilter
RedHill Biopharma Initiates Enforcement Proceedings in Korea
Jun 08 2026
PRnewswire
RedHill Biopharma Advances Opaganib for EVD Treatment
Jun 03 2026
PRnewswire
RedHill Biopharma Advances Opaganib for EVD Treatment
Jun 03 2026
Newsfilter
RedHill Biopharma Advances Opaganib for EVD Treatment Amid Outbreak
Jun 02 2026
PRnewswire
RedHill's RHB-204 Shows Promising Phase 2 Results for Crohn's Disease
Apr 30 2026
PRnewswire
RedHill Reports FY Earnings: Revenue and Cash Position
Apr 27 2026
seekingalpha
Emerging Trends in H. pylori Infection Market
Mar 04 2026
Newsfilter
Analysis of Growth Drivers in the Biliary Tract Cancer Market
Mar 02 2026
Newsfilter
Talicia Full Sales Launch Begins, Unlocking Market Potential
Feb 25 2026
PRnewswire
RedHill Biopharma's RHB-102 Progress Drives 36% Rally, Stock Drops 4.29%
Jan 06 2026
Benzinga
Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%
Jan 06 2026
Benzinga
Show More News
